AMANDA WEATHERFORD: Open Payments
NPI 1659081438 · WAXAHACHIE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$787 in 47 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $191 · 2025 $787
Food & beverage: $780Education: $8
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $212 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $201 |
| Supernus Pharmaceuticals, Inc. | 13 | $180 |
| Axsome Therapeutics, Inc. | 3 | $63 |
| Janssen Pharmaceuticals, Inc | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
Products named: VRAYLAR, CAPLYTA, Qelbree, Auvelity, SPRAVATO, REXULTI, Quviviq, FANAPT.
Industry payments across TX — which companies pay providers there.
